Published by Josh White on 7th December 2022
(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.
URL: http://www.digitallook.com/dl/news/story/33162358/...